Skip to main content
NCBI home page
Elsevier Sponsored Documents logoLink to Elsevier Sponsored Documents
. 2022 Mar;116:174–181. doi: 10.1016/j.ijid.2021.12.318

Prevalence and temporal changes of mutations linked to antimalarial drug resistance in Plasmodium falciparum and Plasmodium vivax in Palawan, Philippines

Alison Paolo N Bareng a,⁎,1, Lynn Grignard b, Ralph Reyes a, Kim Fornace b, Freya Spencer b, Ma Lourdes Macalinao a, Jennifer Luchavez a, Fe Esperanza Espino a, Chris Drakeley b, Julius Clemence R Hafalla b,⁎⁎
PMCID: PMC8866131  PMID: 34883232

Highlights

  • •

    Plasmodium falciparum and Plasmodium vivax isolates from the Philippines were analysed.

  • •

    Varying mutations were found in markers linked to resistance to antimalarial drugs.

  • •

    None of the mutations were particularly of high prevalence.

  • •

    Clear temporal patterns in these mutations were observed within the past 15 years.

  • •

    Decrease in pfcrt and pfmdr mutations are in line with antimalarial policy change.

Keywords: CQ, chloroquine; SP, sulphadoxine/pyrimethamine; AL, artemisinin + lumefantrine; WHO, World Health Organisation; DHFR, dihydrofolate reductase; DHPS, dihydropteroate synthase; CRT, CQ resistance transporter; k13, kelch-13 protein; MDR1, multidrug-resistance 1; Pf, Plasmodium falciparum; Pv, Plasmodium vivax; DNA, deoxyribonucleic acid; PCR, Polymerase chain reaction; TES, Therapeutic Efficacy Surveillance; rRNA, ribosomal ribonucleic acid

KEYWORDS: Malaria, Plasmodium, Drug resistance, Single nucleotide polymorphism, Mutation, Elimination

Abstract

Objective

This study provides 2016 data on the prevalence of key single nucleotide polymorphisms (SNPs) associated with antimalarial drug resistance in Palawan, Philippines. Findings were combined with historical data to model temporal changes in the prevalence of these SNPs in Plasmodium isolates.

Methods

Plasmodium isolates were genotyped using drug resistance markers pfmdr1, pfcrt, pfdhfr, pfdhps, kelch-13, pvmdr1, pvdhfr, and pvdhps. Temporal trends in the probability of mutations were estimated as a function of time using a binomial generalised linear model.

Results

All samples sequenced for Plasmodium falciparum chloroquine markers pfmdr1 and pfcrt had wild-type alleles. Varying mutation patterns were observed for the sulphadoxine/pyrimethamine markers pfdhps and pfdhfr; complete quintuplet mutations were not found. No SNPs were observed for the artemisinin marker kelch-13. For Plasmodium vivax, differing patterns were detected for pvmdr1, pvdhfr, and pvdhps.

Conclusions

The study findings suggest that the current drugs remain effective and that there is limited importation and establishment of resistant parasites in the area. Clear temporal trends were recognised, with prominent decreases in the proportions of pfcrt and pfmdr mutations detected within the past 15 years, consistent with a change in antimalarial drug policy. Continuous surveillance of antimalarial drug resistance is important to support malaria elimination efforts.

Introduction

Malaria remains one of the world's greatest public health challenges. In 2019, it was responsible for nearly 229 million cases and 409 000 deaths worldwide. Whilst 800 000 people remain at high risk of contracting malaria in the Philippines (World Health Organization, 2020), only three provinces reported indigenous cases in 2020; the province of Palawan reported 97% of all the cases in the country (Maru, 2020). Despite current innovative strategies to accelerate global control and elimination, including in the Philippines, with a huge decline in global malaria cases and deaths seen over the past years (World Health Organization, 2020), the emergence and spread of antimalarial drug resistance threatens effective treatment in endemic countries (Menard and Dondorp, 2017). Resistance to commonly used antimalarials has become widespread in low transmission settings, particularly in Southeast Asia (Baird, 2009; Baird et al., 1991; Eyles et al., 1963; Guthmann et al., 2008; Hurwitz et al., 1981; Ratcliff et al., 2007; Young et al., 1963), threatening elimination efforts and compelling countries to modify their treatment strategies and policies.

There is a commitment from the Government of the Philippines to eliminate malaria by 2030 together with the rest of the Asia-Pacific region (Department of Health, 2019, Wen et al., 2016; ). Since the late 1990s, the Philippines has monitored the efficacy of first-line antimalarial drugs for Plasmodium falciparum following the World Health Organization (WHO) protocol for Therapeutic Efficacy Surveillance (TES) (UCSF Global Health Group, 2014). Although drug resistance genotyping of TES isolates has been limited, results led to revisions of the National Malaria Control Programme treatment guidelines for falciparum malaria in 2002, from the use of chloroquine (CQ) alone to CQ plus sulphadoxine/pyrimethamine (SP) combination (UCSF Global Health Group, 2014). Due to observed unacceptable levels of treatment failure to the triple drug combination, the National Malaria Control Programme in 2009 adopted artemisinin + lumefantrine (AL) treatment for P. falciparum (DOH, 2020a). Based on WHO guidelines (World Health Organization, 2015), the Philippines revised its Plasmodium vivax treatment policy from CQ to AL in 2018.

Correlating the data from available clinical studies with genetic markers relating to drug resistance and tracking temporal changes in these markers could be valuable for guiding national malaria treatment policies (Djimdé et al., 2001; Mugittu et al., 2004). SP resistance in P. falciparum is linked to key mutations in dihydrofolate reductase (DHFR) N51, C59, S108 and dihydropteroate synthase (DHPS) S436, A437, K540, A581, A613 (Kublin et al., 2002; Staedke et al., 2004), whilst mutations in CQ resistance transporter (CRT) C72, V73, M74, N75, K76 and multidrug-resistance 1 (MDR1) N86, Y184 are associated with CQ resistance in P. falciparum (Babiker et al., 2001; Das et al., 2014; Fidock et al., 2000). For P. vivax, the role of mutations in the MDR1 orthologue in CQ (Y976, F1076) resistance remains unresolved due to issues with relapse and recrudescence (Price et al., 2012), whilst a panel of mutations in the DHFR (I13, P33, F57, S58, T61, S117, I173) (Imwong et al., 2003) and DHPS (S382, A383, K512, A553, V585) orthologues are associated with an altered clinical response to SP (Hawkins et al., 2007). Additionally, recent studies have suggested that the delay in P. falciparum clearance with the current first-line drug, AL, is linked to mutations in the gene encoding the propeller region of the kelch-13 protein (k13) (Menard, 2016). A combination of clinical AL resistance and k13 mutations has been observed in Southeast Asian countries (Menard, 2016); no confirmation is available from the Philippines.

In order to provide recent data for the Philippines, this study presents findings on the prevalence of mutations based on the genetic markers pfmdr1, pfcrt, pfdhfr, pfdhps, pfk13, pvmdr1, pvdhfr, and pvdhps from samples collected in the Philippines as part of a research study to employ enhanced surveillance methodologies in the country (Reyes et al., 2021). Furthermore, modelling outcomes on temporal trends in the prevalence of these mutations after combining results with historical data are also presented.

Materials and methods

Study population and sample collection

Samples were collected between June and December 2016 in the Municipality of Rizal in the southwest of Palawan Province in the Philippines, as part of a larger survey (Reyes et al., 2021; Figure 1; Supplementary Material Table S1). Palawan is a malaria endemic province, with over 7000 cases reported in 2015 (DOH, 2020b). Rizal municipality recorded the highest number of infections out of a population of approximately 50 000 (PSA, 2020).

Figure 1.

Figure 1

Open in a new tab

Location of the study site. Map highlighting the Municipality of Rizal in the island province of Palawan, Philippines (inset: closer view of the Municipality of Rizal).

Study participants were (1) outpatients of all ages who consulted the rural health unit regardless of symptoms, and (2) the patient's companion. Both the patient and the companion had been residents of the area for at least 7 days prior to the rural health unit visit. Depending on their age group, potential participants were asked to sign an informed consent and/or an assent form. Patients with a serious illness who required urgent care or transportation to a higher-level health facility were excluded. Blood from a finger prick was collected from each participant for microscopy examination of malaria blood film, rapid diagnostic tests, and preparation of dried blood spots for molecular assays. Details of the study design and sampling have been reported previously (Reyes et al., 2021).

DNA extraction and confirmation of Plasmodium sp through nested PCR

Parasite DNA was extracted from filter blood spots using a QIAamp DNA Mini Kit (Qiagen, Germany) with a final elution at 100 μl, or by Chelex extraction method (Bio-Rad Laboratories, Hercules, CA, USA) with a final volume of 180 μl. Two to three blood spots, each with an approximate volume of 20 μl, were used. Both protocols were performed in accordance with the manufacturer's instructions. The extracted DNA samples were stored at −20°C until use. Genus and species-specific Plasmodium DNA in the extracted samples were confirmed using a modified standard nested-PCR assay, which targeted a highly conserved region of the 18s rRNA gene (Fuehrer et al., 2011; Singh and Snounou, 2002; Snounou et al., 1993). The results of the PCR amplifications have been published elsewhere (Reyes et al., 2021).

Amplification and sequencing of P. falciparum and P. vivax drug resistance markers

The prevalence of genetic polymorphisms associated with antimalarial resistance was determined using nested-PCR protocols. Sequences of P. falciparum mdr1, crt, dhfr, dhps, and k13 molecular markers were amplified following protocols performed in published studies (Abdoulaye et al., 2001, Ariey et al., 2014; Humphreys et al., 2007; Lo et al., 2013) . Genetic markers of P. vivax mdr1, dhfr, and dhps were also amplified using published methods (Lekweiry et al., 2012). The numbers of successful amplifications are given in the Results section.

The amplified targets were purified using a QIAquick PCR Purification Kit (Qiagen, Germany). Sequencing reactions were performed using the Big Dye Terminator Cycle Sequencing Kit (Applied Biosystems) following the manufacturer's instructions. The reactions involved the use of the forward and reverse primers of the second round PCR.

Sequence data analysis

Gene sequences were aligned and analysed using CLC Sequence Viewer (version 8). The reference standards were retrieved from PlasmoDB: pfmdr1- (PF3D7_0523000), pfcrt- (PF3D7_0709000), pfdhfr- (PF3D7_0417200), pfdhps- (PF3D7_0810800), k13- (PF3D7_1343700), pvmdr1- (PVX_080100), pvdhfr- (PVX_089950), pvdhps- (PVX_123230).

Modelling of temporal trends in malaria drug resistance markers

Historical data were collated from the literature (Auliff et al., 2006; Bareng et al., 2018; Chen et al., 2005, Chen et al., 2003; Hatabu et al., 2009; Macalinao et al., 2019; Menard, 2016; Saito-Nakano et al., 2008; Sakihama et al., 2007) and unpublished data from (Segubre-Mercado et al., n.d.) and (Bareng et al., n.d.) The compiled data are summarised in Supplementary Material Tables S2 and S3. Along with the data obtained from the current study, the probability of detecting specific mutations was estimated during each time point as a binomial distribution of p mutations detected from n samples screened. For mutations with over two time points, temporal trends in the probability of mutations as a function of time were estimated using a binomial generalised linear model. Analyses were completed and visualised in R statistical software (v. 3.6).

Results

Analysis of single nucleotide polymorphisms (SNPs) in P. falciparum resistance markers

mdr1 and crt, genes associated with CQ resistance in P. falciparum, were successfully amplified and sequenced in 90 and 51 samples, respectively. The amino acid variants and their distribution are summarised in Table 1 and Figure 2. Notably, the wild-type genes corresponding to N86Y186 for pfmdr1 and C72V73M74N75K76 for pfcrt were found in all of the samples sequenced.

Table 1.

Distribution of amino acid variants in the genetic markers conferring antimalarial drug resistance in Plasmodium falciparum and Plasmodium vivax

Genetic markers (Number of genotyped samples) Amino acid position Amino acida Frequency (%)
pfdhfr (n = 123) 51 N (WT) 123 (100%)
59 C (WT) 59 (48%)
R (Mut) 64 (52%)
108 S (WT) 57 (46%)
N (Mut) 66 (54%)
pfdhps (n = 64) 436 F (Mut) 64 (100%)
437 A (WT) 24 (38%)
G (Mut) 40 (63%)
540 K (WT) 63 (98%)
E (Mut) 1 (2%)
581 A (WT) 64 (100%)
613 A (WT) 64 (100%)
pvmdr1 (n = 27) 976 Y (WT) 26 (96%)
F (Mut) 1 (4%)
1076 L (Mut) 27 (100%)
pvdhfr (n = 25) 13 I (WT) 24 (96%)
L (Mut) 1 (4%)
33 P (WT) 25 (100%)
57 F (WT) 24 (96%)
L (Mut) 1 (4%)
58 S (WT) 10 (40%)
R (Mut) 15 (60%)
61 T (WT) 24 (96%)
M (Mut) 1 (4%)
117 S (WT) 9 (36%)
N (Mut) 15 (60%)
T (Mut) 1 (4%)
173 I (WT) 25 (100%)
pvdhps (n = 18) 382 S (WT) 18 (100%)
383 A (WT) 11 (61%)
G (Mut) 7 (39%)
512 K (WT) 18 (100%)
553 A (WT) 17 (94%)
T (Mut) 1 (6%)
Open in a new tab

Genetic markers that do not have mutations are not included in the table.

a

WT = wild-type allele; Mut = mutant allele.

Figure 2.

Figure 2

Open in a new tab

Percentages of haplotypes in drug resistance markers pfmdr1, pfcrt, k13, pvmdr1, and combination alleles dhfr–dhps in Plasmodium isolates.

dhfr, one of the genes associated with SP resistance, was successfully sequenced in 123 samples. Forty-six percent (n = 57) of the isolates sequenced had the wild-type sequence (N51C59S108), whilst the majority (52%, n = 64) of the products had a double mutation at positions N51R59N108, whilst two samples yielded a single mutation at position N51C59N108. For dhps, a gene also associated with SP resistance, 64 of 165 samples were successfully sequenced. No dhps wild-type isolates were identified. Isolates carrying double mutations F436G437K540A581A613 were found in 61% (n = 39) of the samples. Single mutation F436A437K540A581A613 was also present in 24 samples (37%), and one isolate (2%) carried a triple mutant at position F436G437E540A581A613. The proportion of combination alleles dhfr–dhps in P. falciparum species was investigated (Figure 2). The most prevalent combination in P. falciparum carried a wild-type dhfr and double mutation dhps (32%), followed by the double mutant dhfr combined with double mutant dhps (26%). Whilst no wild types were detected for both pfdhfr and pfdhps haplotypes, the full set of quintuplet mutations highly associated with SP treatment failure was not found in this study. Regarding the k13 markers, all sequenced samples (n = 57, 100%) yielded wild-type alleles for codons that are known to be associated with AL susceptibility.

The design of the original study (Reyes et al., 2021) from which these samples were obtained included all health facility attendees, regardless of symptoms. A preliminary analysis was performed to compare the mutations amongst subclinical (participants who presented without fever) and symptomatic (with fever) infections. This analysis revealed that the frequencies of haplotypes with mutation(s) were comparable between the two groups (Supplementary Material Table S4).

Analysis of SNPs in P. vivax genetic markers

Of the 57 confirmed P. vivax samples, genetic markers pvmdr1, pvdhfr, and pvdhps were successfully amplified and sequenced for 27, 25, and 18 samples, respectively, using nested PCR. A summary of the observed allelic distribution of P. vivax markers is given in Table 1 and shown in Figure 2 . Analysis of the pvmdr1 samples showed that the majority (n = 26, 96%) had a single mutation at position Y956L1076, whilst only one sample (n = 1, 4%) carried double mutations F976L1076. No pvmdr1 wild-type isolates were identified. For pvdhfr, wild-type alleles were detected in 32% (n = 8) of the samples. Samples carrying the double mutation at positions I13P33F57R58T61N117I173 had the highest prevalence (56%, n = 14). For the observed pvdhps loci, the haplotype S382A383K512A553 dominated most of the samples with 61% (n = 11), followed by single mutation at position S382G383K512A553 with 33% (n = 6). The prevailing haplotypes with equal numbers of frequencies were double mutation dhfr combined with single mutant dhps and double mutant dhfr and no resistant mutant dhps (29% each) (Figure 2). Given the limited P. vivax isolates in this study, the mutant alleles for dhfr were found to be more frequent in subclinical infections (Supplementary Material Table S4).

Temporal trends in drug resistance markers in the Philippines

To model temporal changes in the prevalence of mutations linked to antimalarial drug resistance in both P. falciparum and P. vivax from different areas in the Philippines, historical and current data were assembled. Data included P. falciparum and P. vivax samples collected as far back as 1985 and 2002, respectively (Auliff et al., 2006; Bareng et al., 2018; Chen et al., 2005, Chen et al., 2003, Hatabu et al., 2009; Macalinao et al., 2019; Menard, 2016; Saito-Nakano et al., 2008; Sakihama et al., 2007). The mean probabilities of detecting mutations and associated 95% confidence intervals for each species are presented in Figure 3 (for P. falciparum) and Figure 4 (for P. vivax). Low sample sizes in the numbers of samples screened historically resulted in wide confidence intervals. For the mutations with sufficient data at multiple time points, clear temporal trends were identified, with marked reductions in the proportions of pfcrt and pfmdr mutations detected within the past 15 years (Figure 3). In contrast, only limited changes were detected in dhfr and dhps mutations in both malaria species, with high probabilities of detecting these mutations at recent time points.

Figure 3.

Figure 3

Open in a new tab

Temporal trends in the probability of mutations for Plasmodium falciparum isolates in the Philippines. (A) Mean probability of mutation and 95% confidence intervals for each sampled time point. (B) Modelled probability of detecting specific mutations over time and associated 95% confidence intervals. Data were assembled from this study and historical findings (Supplementary Material Table S2).

Figure 4.

Figure 4

Open in a new tab

Temporal trends in the probability of mutations for Plasmodium vivax isolates in the Philippines. (A) Mean probability of mutation and 95% confidence intervals for each sampled time point. (B) Modelled probability of detecting specific mutations over time and associated 95% confidence intervals. Data were assembled from this study and historical findings (Supplementary Material Table S3).

Discussion

This aim of this study was to provide up to date evidence on drug resistance through the analysis of SNP markers for common antimalarial drugs in one of most endemic municipalities in the Philippines. Furthermore, given historical data on genetic markers of antimalarial drug resistance in the Philippines, this study offers an analysis of changes over time in these markers since sequencing data became available.

In this study, a low prevalence of mutations was found for drugs for both P. falciparum and P. vivax . Notably, the prevalence of mutations in k13, which is associated with resistance to the first-line drug AL, was 0%. Specifically, low-grade genetic modifications were observed for drug resistance markers for P. falciparum. Results obtained for SP resistance markers were consistent with those of previous studies from the Philippines that were conducted in Cordillera Administrative Region, Davao del Sur, Sultan Kudarat, Zamboanga City, and Palawan (n = 310) in 2003–2007 (Segubre-Mercado et al., n.d.) and in CARAGA region (n = 38) in 2005–2006 (Macalinao et al., 2019) . Similar results were also seen in some other Southeast Asian countries (Biswas et al., 2000; Khim et al., 2005). However, in the present study, the majority of the samples had the F436 mutation in the dhps marker, while in the investigation done by Segubre et al. (Segubre-Mercado et al., n.d.), all samples yielded the wild-type at this position. It should be noted, however, that the detected SNPs may not indicate high-level resistance, as several studies have suggested that quintuple mutation of the combination haplotype pfdhfr and pfdhps is highly likely to be associated with SP treatment failure (Kublin et al., 2002; Picot et al., 2009; Staedke et al., 2004). In contrast, mutations were completely absent in genetic markers associated with CQ resistance pfcrt and pfmdr1. Interestingly, earlier studies with samples collected in 1984–2007 in different locations in the Philippines (Chen et al., 2005; Chen et al., 2003, Hatabu et al., 2009; Macalinao et al., 2019; Saito-Nakano et al., 2008; Sakihama et al., 2007) reported either single C72T76 or double S72T76 mutations in the pfcrt marker. The observed absence of mutation(s) in the molecular markers linked with CQ resistance in this study further supports the reversion of resistance genes in the absence of ongoing drug pressure (Kublin et al., 2003; Mang'era et al., 2012; Mohammed et al., 2013; Pelleau et al., 2015) and presents the possibility of reassessing the therapeutic efficacy of earlier generations of antimalarials. Lastly, the k13 marker was also investigated in this study and it was found that none of the isolates had SNPs at known Asian resistance-conferring alleles: C580Y, R539T, I543T, and Y493H (Menard, 2016). Moreover, no mutations were observed in Philippines samples collected in 2013 (Menard, 2016). Continuous molecular surveillance on the efficacy of these drugs, in addition to clinical studies and in vitro responses, could shed light on the significance of these mutations.

For P. vivax infections, high frequencies of single mutation T976L1076 (96.00%) in the pvmdr1 gene were detected in this study, corroborating the results from previous TES samples collected in Palawan in the years 2009–2012 (Bareng et al., n.d.) and in some Asian countries (Imwong et al., 2008; Kim et al., 2011; Lin et al., 2013; Lu et al., 2011). However, given that CQ is still effective against P. vivax infections, this finding may further provide evidence that this mutation is just a geographical variant and does not indicate CQ resistance (Lekweiry et al., 2012). Moreover, pvdhfr genotyped samples mostly had mutations in only two out of seven alleles, whilst pvdhps sequenced samples were mostly wild types. The results were identical to those of a previous study on samples collected in Palawan (Bareng et al., 2018) and Agusan del Sur (Auliff et al., 2006). These results may provide a further indication of the sensitivity of P. vivax to available treatments. Nevertheless, additional investigations are needed to ascertain whether the observed mutations reflect drug responsiveness or merely another case of geographical variation as described in another study (Lekweiry et al., 2012).

Temporal trends in the mutations linked to antimalarial drug resistance were modelled using historical data and those generated in this study. The historical data included data from all over the country and not only from Rizal, Palawan. As mutations screened at different time points were not designed to be population representative, the modelling results cannot be used to generalise about the prevalence of mutations in wider parasite populations. Yet, the clear temporal trends in the numbers of mutations detected at different sampling points suggests wider changes in the frequency of mutations over time. Nevertheless, the notable decline in the proportions of crt and mdr mutations detected within the past 15 years (prior to the 2016 collection of the samples for this study) is in line with the country's change in antimalarial drug policy in 2009, when the Philippines took up AL treatment for P. falciparum due to response failures to CQ and SP (DOH, 2020a).

It has been suggested that the persistence of some key mutations following years of drug cessation could be attributed to the subclinical and asymptomatic infections harbouring these polymorphisms (Brown et al., 2012; Dokunmu et al., 2019; Nyunt et al., 2017). These infections could cause the continued transmission of parasites harbouring polymorphisms in the population even after an intervention. It is noteworthy that in the current study, participants with subclinical infections were not followed up to determine whether the infections remained subclinical (asymptomatic) or progressed to symptomatic disease. Besides the mutant alleles for P. vivax dhfr, initial analysis showed that participants with subclinical and symptomatic infections harbour parasites with comparable frequencies of haplotypes with mutation(s).

The integration of molecular techniques, such as drug resistance genotyping, with current malaria surveillance methods would be useful to the malaria programme, as it has the potential to allow the emergence of resistant parasites to be monitored continuously in an area . This enhanced surveillance is in line with control and elimination efforts, including the possible widespread use of drugs for mass administration. This study could also be useful in assisting the authorities in implementing the country's malaria treatment policies properly and suggests that population-based drug delivery would not be affected by drug resistance. Further work could also be done to analyse within-host diversity in the parasites, which would identify minor clones that may harbour genes conferring drug resistance.

In conclusion, varying mutation patterns were seen in different genetic markers associated with antimalarial drug resistance, but none at particularly high prevalence. Mutations were still present in SP markers pfdhfr and pfdhps; similar observations were seen with TES samples collected in 2001. In contrast, the observed alleles in genetic markers linked with CQ resistance in P. falciparum have all turned into wild-type genotypes after 15 years; these possibly reverted back to the original gene structure. SNPs associated with P. vivax resistance were still identified in both CQ and SP markers, similar to what was observed in TES 2009 samples. The roles of these mutations require interpretation alongside clinical and in vivo studies. Consequently, given the regional concerns around resistance, further monitoring of drug resistance using molecular and clinical responses seems worthwhile, as part of control and elimination efforts. In summary, the data and results of this study indicate that (1) the current first-line treatments should be effective, and (2) there has been relatively little importation and successful establishment of parasites from areas where resistance and resistance markers are more established.

WEB REFERENCES

Department of Health (DOH), Republic of the Philippines, Administrative order No. 2009-0001: “Revised policy and guidelines on the diagnosis and treatment of malaria”. DOH website (2020) [https://dmas.doh.gov.ph:8083/Rest/GetFile?id=336782]. Date (Accessed: 09 November 2020).

Department of Health (DOH), Republic of the Philippines, Statistics: Distribution of cases in the Philippines (2020) [https://doh.gov.ph/malaria-control-program]. Date (Accessed: 09 November 2020).

Department of Health (DOH), Republic of the Philippines, PHL Malaria-free by 2030. DOH website (2019). [https://doh.gov.ph/press-release/Phl-Malaria-Free-by-2030-DOH] (Accessed: 24 September 2021)

Maru D. Philippines on track to eradicate malaria by 2030-WHO. ABS-CBN News. [https://news.abs-cbn.com/news/02/13/20/philippines-on-track-to-eradicate-malaria-by-2030-who] (Accessed: 24 September 2021).

Philippine Statistics Authority (PSA), Highlights of Philippine Population 2015 Census of Population, R04B (2020) [https://psa.gov.ph/population-and-housing/statistical-tables/title/Highlights%20of%20the%20Philippine%20Population%20%202015%20Census%20of%20Population]. Date (Accessed: 09 November 2020).

Acknowledgments

Acknowledgements

Gratitude is expressed to the ENSURE study team of Research Institute for Tropical Medicine (RITM) and The London School of Hygiene and Tropical Medicine (LSHTM) for the technical and administrative support, as well as to the local community of Rizal in Palawan for their participation in this study.

Declarations

Funding: This study was supported by the Newton Fund; Department of Science and Technology-Philippine Center for Health Research and Development (DOST-PCHRD); and UK-Medical Research Council (UK-MRC) Grant MR/N019199/1.

Ethical clearance: Ethical clearance for this project was approved by RITM and the LSHTM institutional review boards (RITM 2016-04 and LSHTM IRB 11597).

Conflict of interest: The authors declare that they have no competing interests.

Footnotes

Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.ijid.2021.12.318.

Contributor Information

Alison Paolo N. Bareng, Email: pbareng@yahoo.com.

Julius Clemence R. Hafalla, Email: Julius.Hafalla@lshtm.ac.uk.

Appendix. Supplementary materials

mmc1.docx (39.1KB, docx)

REFERENCES

  1. Ariey F, Witkowski B, Amaratunga C, Johann B-, Langlois A-C, Khim N, et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature. 2014:50–55. doi: 10.1038/nature12876. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Auliff A, Wilson D, Russel B, Gao Q, Gen N, Anh LN, et al. Amino acid mutations in Plasmodium vivax DHFR and DHPS from several geographical regions and susceptibility to antifolate drugs. ASTMH. 2006;75:617–621. doi: 10.4269/ajtmh.2006.75.617. [DOI] [PubMed] [Google Scholar]
  3. Babiker H, Pringle S, Abdel-Muhsin A, Mackinnon M, Hunt P, Walliker D. High-level chloroquine resistance in Sudanese isolates of Plasmodium falciparum is associated with mutations in the chloroquine resistance transporter gene pfcrt and the multidrug resistance gene pfmdr1. The Journal of Infectious Diseases. 2001;183:1535–1538. doi: 10.1086/320195. [DOI] [PubMed] [Google Scholar]
  4. Baird JK. Resistance to Therapies for Infection by Plasmodium vivax. Clinical Microbiology Reviews. 2009;22:508–534. doi: 10.1128/CMR.00008-09. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Baird JK, Basri H, Purnomo Bangs MJ, Subianto B, Patchen LC, et al. Resistance to chloroquine by Plasmodium vivax in Irian Jaya, Indonesia. American Journal of Tropical Medicine and Hygiene. 1991;44:547–552. doi: 10.4269/ajtmh.1991.44.547. [DOI] [PubMed] [Google Scholar]
  6. Bareng Alison Paolo N, Segubre-Mercado Edelwisa, Calugay Ronie, Galit Sherwin, Espino Fe Esperanza Molecular Surveillance of Chloroquine Resistant Plasmodium vivax using pvmdr1 Gene Marker in Selected Municipalities in Palawan, Philippines. Unpublished results Unpublished results. In preparation.
  7. Bareng AP, Espino FE, Chaijaroenkul W, Na-Bangchang K. Molecular monitoring of dihydrofolatereductase (dhfr) and dihydropteroatesynthetase (dhps) associated with sulfadoxine-pyrimethamine resistance in Plasmodium vivax isolates of Palawan, Philippines. Acta Tropica. 2018;180 doi: 10.1016/j.actatropica.2018.01.006. [DOI] [PubMed] [Google Scholar]
  8. Biswas S, Escalante A, Chaiyaroj S, Angkasekwinai P, Lal AA. Prevalence of point mutations in the dihydrofolate reductase and dihydropteroate synthetase genes of Plasmodium falciparum isolates from India and Thailand: A molecular epidemiologic study. Tropical Medicine and International Health. 2000;5:737–743. doi: 10.1046/j.1365-3156.2000.00632.x. [DOI] [PubMed] [Google Scholar]
  9. Brown T, Smith LS, Oo EKS, Shawng K, Lee TJ, Sullivan D, et al. Molecular surveillance for drug-resistant Plasmodium falciparum in clinical and subclinical populations from three border regions of Burma/Myanmar: cross-sectional data and a systematic review of resistance studies. Malar J. 2012;11:333. doi: 10.1186/1475-2875-11-333. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Chen N, Kyle DE, Pasay C, Fowler EV, Baker J, Peters JM, et al. pfcrt Allelic Types with Two Novel Amino Acid Mutations in Chloroquine-Resistant Plasmodium falciparum Isolates from the Philippines. Antimicrobial Agents and Chemotherapy. 2003;47:3500–3505. doi: 10.1128/AAC.47.11.3500-3505.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Chen N, Wilson DW, Pasay C, Bell David, Martin LB, Kyle D, et al. Origin and Dissemination of Chloroquine-Resistant Plasmodium falciparum with Mutant pfcrt Alleles in the Philippines. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. 2005;49:2102–2105. doi: 10.1128/AAC.49.5.2102-2105.2005. ‡. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Das S, Mahapatra SK, Tripathy S, Chattopadhyay S, Dash SK, Mandal D, et al. Double Mutation in the pfmdr1 Gene Is Associated with Emergence of Chloroquine-Resistant Plasmodium falciparum Malaria in Eastern India. Am Soc Microbiol. 2014:5909–5915. doi: 10.1128/AAC.02762-14. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Department of Health https://doh.gov.ph/press-release/Phl-Malaria-Free-by-2030-DOH
  14. Djimdé A, Doumbo O, Steketee R, Plowe CV. Application of a molecular marker for surveillance of chloroquine-resistant falciparum malaria. The Lancet. 2001:890. doi: 10.1016/S0140-6736(01)06040-8. –1. [DOI] [PubMed] [Google Scholar]
  15. Abdoulaye Djimdé, Doumbo OK, Cortese JF, Kayentao K, Doumbo S, Diourté Y, et al. A molecular marker for chloroquine-resistant falciparum malaria. New England Journal of Medicine. 2001;344:257–263. doi: 10.1056/NEJM200101253440403. [DOI] [PubMed] [Google Scholar]
  16. Dokunmu TM, Adjekukor CU, Yakubu OF, Bello AO, Adekoya JO, Akinola O, et al. Asymptomatic malaria infections and Pfmdr1 mutations in an endemic area of Nigeria. Malar J. 2019;18:218. doi: 10.1186/s12936-019-2833-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Eyles DE, Hoo CC, Warren M, Sandosham AA. Plasmodium falciparum resistant to chloroquine in Cambodia. The American Journal of Tropical Medicine and Hygiene. 1963;12:840–843. doi: 10.4269/ajtmh.1963.12.840. [DOI] [PubMed] [Google Scholar]
  18. Fidock D, Nomura T, Talley A, Cooper RA, Dzekunov S, Ferdig M, et al. Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. Molecular Cell. 2000;6:861–871. doi: 10.1016/S1097-2765(05)00077-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Fuehrer H-P, Fally MA, Habler VE, Starzengruber P, Swoboda P, Noedl H. Novel Nested Direct PCR Technique for Malaria Diagnosis Using Filter Paper Samples. Journal of Clinical Microbiology. 2011;49:1628–1630. doi: 10.1128/JCM.01792-10. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Guthmann JP, Pittet A, Lesage A, Imwong M, Lindegardh N, Min Lwin M, et al. Plasmodium vivax resistance to chloroquine in Dawei, southern Myanmar. Tropical Medicine and International Health. 2008;13:91–98. doi: 10.1111/j.1365-3156.2007.01978.x. [DOI] [PubMed] [Google Scholar]
  21. Hatabu T, Iwagami M, Kawazu S, Taguchi N, Kawazu S, Taguchi N, et al. Association of molecular markers in Plasmodium falciparum crt and mdr1 with in vitro chloroquine resistance: a Philippine study. Parasitology International. 2009;58:166–170. doi: 10.1016/j.parint.2009.01.010. [DOI] [PubMed] [Google Scholar]
  22. Hawkins VN, Joshi H, Rungsihirunrat K, Na-Bangchang K, Sibley CH. Antifolates can have a role in the treatment of Plasmodium vivax. Trends in Parasitology. 2007;23:213–222. doi: 10.1016/j.pt.2007.03.002. [DOI] [PubMed] [Google Scholar]
  23. Humphreys GS, Merinopoulos I, Ahmed J, Whitty CJM, Mutabingwa TK, Sutherland CJ, et al. Amodiaquine and Artemether-Lumefantrine Select Distinct Alleles of the Plasmodium falciparum mdr1 Gene in Tanzanian Children Treated for Uncomplicated Malaria. Antimicrobial Agents and Chemotherapy. 2007;51:991–997. doi: 10.1128/AAC.00875-06. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Hurwitz E, Johnson D, Campbell C. Resistance of Plasmodium falciparum malaria to sulfadoxine-pyrimethamine ('Fansidar’) in a refugee camp in Thailand. The Lancet. 1981;317:1068–1070. doi: 10.1016/S0140-6736(81)92239-X. [DOI] [PubMed] [Google Scholar]
  25. Imwong M, Pukrittayakamee S, Pongtavornpinyo W, Nakeesathit S, Nair S, Newton P, et al. Gene amplification of the multidrug resistance 1 gene of Plasmodium vivax isolates from Thailand, Laos, and Myanmar. Am Soc Microbiol. 2008:2657–2659. doi: 10.1128/AAC.01459-07. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Imwong M, Pukrittayakamee S, Rénia L, Letourneur F, Charlieu J-P, Leartsakulpanich U, et al. Novel Point Mutations in the Dihydrofolate Reductase Gene of Plasmodium vivax: Evidence for Sequential Selection by Drug Pressure. AAC. 2003;47:1514–1521. doi: 10.1128/AAC.47.5.1514-1521.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Khim N, Bouchier C, Se Ekala M-T, Incardona S, Lim P, Legrand E, et al. Countrywide Survey Shows Very High Prevalence of Plasmodium falciparum Multilocus Resistance Genotypes in Cambodia. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. 2005;49:3147–3152. doi: 10.1128/AAC.49.8.3147-3152.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Kim Y, Kim C, Park I, Kim H, Choi J, Kim J. Therapeutic efficacy of chloroquine in Plasmodium vivax and the pvmdr1 polymorphisms in the Republic of Korea under mass chemoprophylaxis. Am J Trop Med Hyg. 2011:532–534. doi: 10.4269/ajtmh.2011.10-0486. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Kublin J, Cortese J, Njunju E, Mukadam R, Wirima J, Kazembe P, et al. Reemergence of Chloroquine-Sensitive Plasmodium falciparum Malaria after Cessation of Chloroquine Use in Malawi. The Journal of Infectious Diseases. 2003;187:1870–1875. doi: 10.1086/375419. [DOI] [PubMed] [Google Scholar]
  30. Kublin J, Dzinjalamala F, Kamwendo D, Malkin E, Cortese J, Martino L, et al. Molecular Markers for Failure of Sulfadoxine-Pyrimethamine and Chlorproguanil-Dapsone Treatment of Plasmodium falciparum Malaria. The Journal of Infectious Diseases. 2002;185:380–388. doi: 10.1086/338566. [DOI] [PubMed] [Google Scholar]
  31. Lekweiry KM, Boukhary AOMS, Gaillard T, Wurtz N, Hafid JE, Trape J-F, et al. Molecular surveillance of drug-resistant Plasmodium vivax using pvdhfr, pvdhps and pvmdr1 markers in Nouakchott, Mauritania. Journal of Antimicrobial Chemotherapy. 2012:367–374. doi: 10.1093/jac/dkr464. [DOI] [PubMed] [Google Scholar]
  32. Lin JT, Patel JC, Kharabora O, Sattabongkot J, Muth S, Ubalee R, et al. Plasmodium vivax isolates from Cambodia and Thailand show high genetic complexity and distinct patterns of P. vivax multidrug resistance gene 1 (pvmdr1) polymorphisms. American Journal of Tropical Medicine and Hygiene. 2013;88:1116–1123. doi: 10.4269/ajtmh.12-0701. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Lo AC, Faye B, Ba EH, Cisse B, Tine R, Abiola A, et al. Prevalence of molecular markers of drug resistance in an area of seasonal malaria chemoprevention in children in Senegal. Malaria Journal. 2013;12 doi: 10.1186/1475-2875-12-137. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Lu F, Lim C, Nam D, Kim K, Lin K, Kim T, et al. Genetic polymorphism in pvmdr1 and pvcrt-o genes in relation to in vitro drug susceptibility of Plasmodium vivax isolates from malaria-endemic countries. Acta Tropica. 2011;117:69–75. doi: 10.1016/j.actatropica.2010.08.011. [DOI] [PubMed] [Google Scholar]
  35. Macalinao M, Segubre-Mercado E, Calugay RJ, Galit SA, Haidee J, Acuna L, et al. Detection of antimalarial drug resistance markers in Plasmodium falciparum samples from CARAGA, Philippines: a retrospective study. Philippine Science Letters. 2019;12 [Google Scholar]
  36. Mang'era CM, Mbai FN, Omedo IA, Mireji PO, Omar SA. Changes in genotypes of Plasmodium falciparum human malaria parasite following withdrawal of chloroquine in Tiwi, Kenya. Acta Tropica. 2012;123:202–207. doi: 10.1016/j.actatropica.2012.05.007. [DOI] [PubMed] [Google Scholar]
  37. Maru https://news.abs-cbn.com/news/02/13/20/philippines-on-track-to-eradicate-malaria-by-2030-who
  38. Menard D. A Worldwide Map of Plasmodium falciparum K13-Propeller Polymorphisms. New England Journal of Medicine. 2016;374:2453–2464. doi: 10.1056/NEJMoa1513137. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Menard D, Dondorp A. Antimalarial Drug Resistance: A Threat to Malaria Elimination. Cold Spring Harb Perspect Med. 2017 doi: 10.1101/cshperspect.a025619. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Mohammed A, Ndaro A, Kalinga A, Manjurano A, Mosha JF, Mosha DF, et al. Trends in chloroquine resistance marker, Pfcrt-K76T mutation ten years after chloroquine withdrawal in Tanzania. Malaria Journal. 2013;12 doi: 10.1186/1475-2875-12-415. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Mugittu K, Ndejembi M, Malisa A, Lemnge M, Premji Z, Mwita A, et al. Therapeutic efficacy of sulfadoxine-pyrimethamine and prevalence of resistance markers in Tanzania prior to revision of malaria treatment policy: Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase mutations in monitoring in vivo resistance. American Journal of Tropical Medicine and Hygiene. 2004;71:696–702. doi: 10.4269/ajtmh.2004.71.696. [DOI] [PubMed] [Google Scholar]
  42. Nyunt MH, Shein T, Zaw NN, Han SS, Muh F, Lee S-K, et al. Molecular Evidence of Drug Resistance in Asymptomatic Malaria Infections, Myanmar, 2015. Emerg Infect Dis. 2017;23:517–520. doi: 10.3201/eid2303.161363. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Pelleau S, Moss EL, Dhingra SK, Volney B, Casteras J, Gabryszewski SJ, et al. Adaptive evolution of malaria parasites in French Guiana: Reversal of chloroquine resistance by acquisition of a mutation in pfcrt. National Acad Sciences. 2015;112:11672–11677. doi: 10.1073/pnas.1507142112. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Picot S, Olliaro P, De Monbrison F, Bienvenu AL, Price RN, Ringwald P. A systematic review and meta-analysis of evidence for correlation between molecular markers of parasite resistance and treatment outcome in falciparum malaria. Malaria Journal. 2009;8 doi: 10.1186/1475-2875-8-89. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Price RN, Auburn S, Marfurt J, Cheng Q. Phenotypic and genotypic characterisation of drug-resistant Plasmodium vivax. Trends in Parasitology. 2012;28:522–529. doi: 10.1016/j.pt.2012.08.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Ratcliff A, Siswantoro H, Kenangalem E, Brockman A, Eidstein M, Ebsworth E, et al. Therapeutic response of multidrug-resistant Plasmodium falciparum and P. vivax to chloroquine and sulfadoxine–pyrimethamine in southern Papua, Indonesia. Transactions of the Royal Society of Tropical Medicine and Hygiene. 2007;101:351–359. doi: 10.1016/j.trstmh.2006.06.008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Reyes RA, Fornace KM, Macalinao MLM, Boncayao BL, De La Fuente ES, Sabanal HM, et al. Enhanced Health Facility Surveys to Support Malaria Control and Elimination across Different Transmission Settings in the Philippines. The American Journal of Tropical Medicine and Hygiene. 2021 doi: 10.4269/ajtmh.20-0814. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Saito-Nakano Y, Tanabe K, Kamei K, Iwagami M, Komaki-Yasuda K, Kawazu SI, et al. Genetic evidence for Plasmodium falciparum resistance to chloroquine and pyrimethamine in Indochina and the Western Pacific between 1984 and 1998. American Journal of Tropical Medicine and Hygiene. 2008;79:613–619. doi: 10.4269/ajtmh.2008.79.613. [DOI] [PubMed] [Google Scholar]
  49. Sakihama N, Nakamura M, Palanca A, Argubano R, Realon E, Larracas A, et al. Allelic diversity in the merozoite surface protein 1 gene of Plasmodium falciparum on Palawan Island, the Philippines. Parasitology International. 2007;53:185–194. doi: 10.1016/j.parint.2007.01.011. [DOI] [PubMed] [Google Scholar]
  50. Segubre-Mercado Edelwisa, Orbina Jun, Bustos Dorin The geographic distribution and prevalence of Plasmodium falciparum resistant genotypes in the Philippines. Unpublished results Unpublished results. In preparation.
  51. Singh B, Snounou G. Nested PCR analysis of Plasmodium parasites. Springer. 2002;72:189–203. doi: 10.1385/1-59259-271-6:189. [DOI] [PubMed] [Google Scholar]
  52. Snounou G, Viriyakosol S, Jarra W, Thaithong S, Brown K. Identification of the four human malarial species in field samples by the polymerase chain reaction and detection of a high prevalence of mixed infections. Molecular and Biochemical Parasitology. 1993;58:283–292. doi: 10.1016/0166-6851(93)90050-8. [DOI] [PubMed] [Google Scholar]
  53. Staedke SG, Sendagire H, Lamola S, Kamya MR, Dorsey G, Rosenthal PJ. Relationship between age, molecular markers, and response to sulphadoxine-pyrimethamine treatment in Kampala, Uganda. Tropical Medicine and International Health. 2004;9:624–629. doi: 10.1111/j.1365-3156.2004.01239.x. [DOI] [PubMed] [Google Scholar]
  54. UCSF Global Health Group. Eliminating Malaria Case study 6: Progress towards subnational elimination in the Philippines. 2014.
  55. Wen S, Harvard KE, Gueye CS, Canavati SE, Chancellor A, Ahmed B-N, et al. Targeting populations at higher risk for malaria: a survey of national malaria elimination programmes in the Asia Pacific. Malar J. 2016;15:271. doi: 10.1186/s12936-016-1319-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. World Health Organization. Guidelines for the treatment of malaria. 3rd ed. 2015. [PubMed]
  57. World Health Organization, World Health Organization . World malaria report 2020: 20 years of global progress and challenges. World Health Organization; Geneva: 2020. [Google Scholar]
  58. Young MD, Contacos PG, Stitcher JE, Millar JW. Drug resistance in Plasmodium falciparum from Thailand. The American Journal of Tropical Medicine and Hygiene. 1963;12:305–314. doi: 10.4269/ajtmh.1963.12.305. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

mmc1.docx (39.1KB, docx)

RESOURCES